USAntibiotics, the Nation's Sole Amoxicillin Manufacturing Facility, Launches Production to Secure Critical Supply Chain

BRISTOL, Tenn., Nov. 30, 2021 /PRNewswire/ -- USAntibiotics, the sole-licensed American maker of penicillin-based Amoxil^® (amoxicillin) and Augmentin^® (amoxicillin clavulanate), today announced that it has relaunched production of the nation's only Amoxicillin manufacturing facility. When it reaches full production capacity in 2022, it will be able to produce enough Amoxicillin products to meet 100 percent of the nation's demand for these essential medications.

With supply chain issues impacting healthcare, the buildout of U.S. antibiotics capacity is vital to defend America's national security and public health.

"As Americans are trying to get holiday gifts into the country, we have all become painfully aware of the fragility of global supply chains – but this pales in comparison to problems caused by a disruption in obtaining life-saving medications," said Shane Jackson, president of Jackson Healthcare, which purchased the production facility out of bankruptcy in the spring of 2021.

"We are so proud to have taken this step to produce these American-made antibiotics," added Jackson. "It is vital to our nation's health to produce high-quality antibiotics and to build a large enough stockpile of such critical medicine to guarantee availability. It's something no nation can live without."

Currently, 30 percent of all antibiotics prescribed in the U.S. are Amoxicillin products.

"The ability to produce these antibiotics in the United States strengthens our ability to fight threats from pandemics to bio-terrorism to common diseases," Jackson said. "They are essential to the health and safety of our nation."

USAntibiotics' manufacturing facility, located in Upper East Tennessee, is currently producing 1.4 million tablets daily but will ramp up in the weeks and months ahead. It has the capacity to produce 2.2 billion tablets and 312 million capsules of Amoxicillin on an annual basis. In package form, that equates to approximately 48 million bottles of tablets and 13.5 million bottles of capsules containing the life-saving medications.

USAntibiotics can also eventually store enough Amoxicillin to meet five-years' worth of demand of its products.

In 2008, every U.S.-administered dose of Amoxil and Augmentin was produced in the U.S. By 2019, however, the U.S. Commerce Department reported that 80 percent of the supply of US antibiotics were made in China.

The supply chain shortage has hit across all segments of healthcare, and the American Society of Health- System Pharmacists and the Food and Drug Administration have an evolving list of more than 100 medications that are in short supply.

About USAntibiotics  
USAntibiotics is the only U.S. manufacturer of amoxicillin and amoxicillin clavulanate, commonly known as Amoxil and Augmentin. Based in Bristol, Tenn., it operates a world-class, 394,000 square foot antibiotic production facility with the sole focus of making quality, life-saving antibiotics widely available for the benefit of all Americans. USAntibiotics is part of the Jackson Healthcare^® family of companies. For more information, visit www.us-antibiotics.com. 

About Jackson Healthcare 
Jackson Healthcare^® is a family of highly specialized healthcare staffing, search and technology companies. With a mission to improve the delivery of patient care and the lives of everyone it touches, it helps healthcare facilities across the country serve more than 10 million patients each year. Backed by more than 1,500 associates and with over $1.4 billion in annual revenue, Jackson Healthcare is a top three U.S. healthcare staffing firm. In addition to being Great Place to Work certified, it is consistently named an employer of choice, having been nationally recognized as a best workplace in healthcare, a best workplace for women and a best workplace for millennials, as well as being named one of 2020's healthiest employers. Learn more at www.jacksonhealthcare.com.

SOURCE USAntibiotics